Estrella Immunopharma Inc. announced updated clinical data from the ongoing STARLIGHT-1 Phase I trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). The results were presented in an oral session at the 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood & Marrow Transplant Research (ASTCT & CIBMTR). According to the data, EB103 demonstrated a 100% Complete Response $(CR)$ rate in the high-dose cohort at Month 1, with all patients who achieved CR remaining in remission at the time of data cutoff. No treatment-related serious adverse events were reported in the study population, which included high-risk patients ineligible for existing commercial CD19 therapies. The median duration of complete response has not yet been reached, with current response durations ranging from 3 to 18 months. The company also reported a complete response in a patient with Primary Central Nervous System Lymphoma, a subtype with historically poor prognosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260208494044) on February 09, 2026, and is solely responsible for the information contained therein.